{"id":"NCT01183013","sponsor":"Boehringer Ingelheim","briefTitle":"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks","officialTitle":"A Randomised, Double-blind Parallel Group Study to Compare the Efficacy and Safety of Initial Combination Therapy With Linagliptin 5 mg + Pioglitazone 15 mg, 30 mg, or 45 mg, vs. Monotherapy With Pioglitazone (15 mg, 30 mg, or 45 mg) or Linagliptin 5 mg Once Daily for 30 Weeks, Followed by a Blinded Trial Period on Linagliptin 5 mg + Pioglitazone 30 or 45 mg Versus Pioglitazone Monotherapy 30 or 45 mg or Linagliptin 5 mg for up to 54 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control on Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2010-08-17","resultsPosted":"2014-04-21","lastUpdate":"2014-10-20"},"enrollment":936,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Pioglitazone 15 mg","otherNames":[]},{"type":"DRUG","name":"Pioglitazone 45 mg","otherNames":[]},{"type":"DRUG","name":"Pioglitazone 30 mg","otherNames":[]},{"type":"DRUG","name":"Linagliptin 5mg / Pioglitazone 45 mg FDC","otherNames":[]},{"type":"DRUG","name":"Linagliptin 5mg / Pioglitazone 30 mg FDC","otherNames":[]},{"type":"DRUG","name":"Linagliptin 5mg","otherNames":[]},{"type":"DRUG","name":"Linagliptin 5mg / Pioglitazone 15 mg FDC","otherNames":[]}],"arms":[{"label":"Pioglitazone 15 mg","type":"ACTIVE_COMPARATOR"},{"label":"Pioglitazone 30 mg","type":"ACTIVE_COMPARATOR"},{"label":"Pioglitazone 45 mg","type":"ACTIVE_COMPARATOR"},{"label":"Linagliptin 5mg","type":"ACTIVE_COMPARATOR"},{"label":"Linagliptin 5mg / Pioglitazone 15 mg","type":"EXPERIMENTAL"},{"label":"Linagliptin 5mg / Pioglitazone 30 mg","type":"EXPERIMENTAL"},{"label":"Linagliptin 5mg / Pioglitazone 45 mg","type":"EXPERIMENTAL"}],"summary":"The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30 mg, or 45 mg, administered orally once daily), and linagliptin (5 mg, administered orally once daily). In addition, durability of treatment effect and safety under chronic treatment conditions will be investigated.","primaryOutcome":{"measure":"Change From Baseline in HbA1c After 30 Weeks of Treatment.","timeFrame":"Baseline and 30 weeks","effectByArm":[{"arm":"Pio15","deltaMin":-0.66,"sd":0.09},{"arm":"Pio30","deltaMin":-0.69,"sd":0.09},{"arm":"Pio45","deltaMin":-0.87,"sd":0.09},{"arm":"Lina5","deltaMin":-0.39,"sd":0.09},{"arm":"Lina5Pio15","deltaMin":-0.83,"sd":0.09},{"arm":"Lina5Pio30","deltaMin":-1.06,"sd":0.09},{"arm":"Lina5Pio45","deltaMin":-1.28,"sd":0.09}],"pValues":[{"comp":"OG000 vs OG004","p":"0.1571"},{"comp":"OG001 vs OG005","p":"0.0016"},{"comp":"OG002 vs OG006","p":"0.0006"},{"comp":"OG003 vs OG004","p":"0.0003"},{"comp":"OG003 vs OG005","p":"<0.0001"},{"comp":"OG003 vs OG006","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":132,"countries":["United States","Estonia","Germany","Latvia","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":131},"commonTop":["Oedema peripheral","Back pain","Hyperglycaemia","Nasopharyngitis","Urinary tract infection"]}}